ESPR — Esperion Therapeutics, Inc. stock price, charts and financials
QT84Esperion Therapeutics, Inc.Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
3.18
+0.00%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -0.06 | Insider Own | 11.16% | Shs Outstand | 207.91M | Perf Week | 0.63% |
| Market Cap | 661.15M | Forward P/E | 11.71 | EPS next Y | 0.27 | Insider Trans | -0.49% | Shs Float | 207.91M | Perf Month | 0.95% |
| Enterprise Value | 1.05B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 8.37% | Perf Quarter | 43.24% |
| Income | -6.15M | P/S | 1.58 | EPS this Y | 33.33% | Inst Trans | - | Short Ratio | 1.33 | Perf Half Y | -18.04% |
| Sales | 418.25M | P/B | - | EPS next Y | 779.18% | ROA | -1.60% | Short Interest | 17.40M | Perf YTD | -14.05% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | 1.99% | 52W High | 4.18 -23.92% | Perf Year | 167.23% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | 30.98% | 52W Low | 1.10 189.09% | Perf 3Y | 110.60% |
| Dividend Est. | 3.16 (99.37%) | EV/EBITDA | 26.29 | Sales past 3/5Y | 75.15% 12.07% | Gross Margin | 65.00% | Volatility | 0.38% 0.54% | Perf 5Y | -83.99% |
| Dividend TTM | 3.16 (99.37%) | EV/Sales | 2.51 | EPS Y/Y TTM | 78.57% | Oper. Margin | 18.12% | ATR (14) | 0.02 | Perf 10Y | -69.28% |
| Dividend Ex-Date | Jul 13, 2026 | Quick Ratio | 1.18 | Sales Y/Y TTM | 25.60% | Profit Margin | -1.77% | RSI (14) | 64.48 | Recom | 2.76 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.53 | EPS Q/Q | 52.38% | SMA20 | 0.49% | Beta | 1.10 | Target Price | 3.19 |
| Payout | 0.00% | Debt/Eq | - | Sales Q/Q | 23.08% | SMA50 | 1.11% | Rel Volume | 0.00 | Prev Close | 3.18 |
| Employees | 294 | LT Debt/Eq | -1.52 | Earnings | Aug 04 | SMA200 | 3.85% | Avg Volume | 15.12M | Price | 3.18 |
| IPO Date | Jun 26, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -169.23% -5.23% | Net Debt/EBITDA | 9.72 | Volume | 0 | Change | 0.00% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-04-26 | Downgrade | Needham | Buy → Hold | |
| May-01-26 | Reiterated | Jefferies | Hold | $3.28 |
| May-01-26 | Reiterated | Piper Sandler | $9.00 → $3.16 | |
| May-01-26 | Reiterated | Cantor Fitzgerald | $9.00 → $3.16 | |
| May-01-26 | Downgrade | HC Wainwright & Co. | Buy → Neutral | $3.16 |
| Nov-24-25 | Initiated | Piper Sandler | Overweight | $9.00 |
| Sep-25-25 | Reiterated | Cantor Fitzgerald | $7.00 → $9.00 | |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight | $8.00 |
| Jun-20-24 | Downgrade | B of A Securities | Neutral → Underperform | |
| Jun-15-23 | Upgrade | B of A Securities | Underperform → Buy |
Latest News
Jul-20-26
Jul-20-2605:11PM
Jul-10-26
Jul-10-2608:02AM
Jul-01-26
Company
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 417 | 403 | 332 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 147 | 129 | 69 | — | — | — | — | — | — | |
| Gross Profit | 273 | 274 | 264 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 166 | 166 | 163 | — | — | — | — | — | — | |
| Research and Development | 44 | 48 | 46 | — | — | — | — | — | — | |
| Other Operating Expense | -14 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | 75 | 60 | 54 | — | — | — | — | — | — | |
| Interest Expense | 45 | 85 | 59 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -35 | 3 | -47 | — | — | — | — | — | — | |
| Net Income Before Taxes | -5 | -21 | -52 | — | — | — | — | — | — | |
| Income Taxes | 2 | 2 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -7 | -23 | -52 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -7 | -23 | -52 | — | — | — | — | — | — | |
| Net Income | -7 | -23 | -52 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.02 | -0.11 | -0.28 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.02 | -0.11 | -0.28 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.06 | -0.11 | -0.28 | — | — | — | — | — | — | |
| EBITDA | 40 | 64 | 8 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.91 | 1.91 | 1.24 | — | — | — | — | — | — | |
| Gross Margin | 65.47 | 67.99 | 79.52 | — | — | — | — | — | — | |
| Operating Margin | 17.99 | 14.89 | 16.27 | — | — | — | — | — | — | |
| Net Margin | -1.68 | -5.71 | -15.66 | — | — | — | — | — | — | |
| Shares Outstanding | 251 | 208 | 187 | — | — | — | — | — | — | |
| Market Capitalization | 798 | 770 | 411 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Looker Benjamin | Chief Legal Officer | Jun 17 '26 | Sale | 3.15 | 11,824 | 37,305 | 667,524 | Jun 18 |
| Koenig Sheldon L. | President and CEO | Jun 17 '26 | Sale | 3.15 | 53,588 | 169,070 | 2,119,111 | Jun 18 |
| Halladay Benjamin | Chief Financial Officer | Jun 17 '26 | Sale | 3.15 | 10,773 | 33,989 | 702,829 | Jun 18 |
| Looker Benjamin | Chief Legal Officer | Mar 17 '26 | Sale | 2.70 | 5,708 | 15,429 | 679,348 | Mar 18 |
| Koenig Sheldon L. | President and CEO | Mar 17 '26 | Sale | 2.72 | 25,578 | 69,547 | 2,172,699 | Mar 18 |
| Halladay Benjamin | Chief Financial Officer | Mar 17 '26 | Sale | 2.71 | 6,424 | 17,377 | 713,602 | Mar 18 |
| Looker Benjamin | General Counsel | Jan 20 '26 | Sale | 2.88 | 1,689 | 4,868 | 384,216 | Jan 21 |
| Koenig Sheldon L. | President and CEO | Dec 17 '25 | Sale | 3.67 | 48,244 | 177,200 | 1,470,587 | Dec 18 |
| Halladay Benjamin | Chief Financial Officer | Dec 17 '25 | Sale | 3.67 | 7,337 | 26,905 | 467,525 | Dec 18 |
| Looker Benjamin | General Counsel | Dec 17 '25 | Sale | 3.67 | 6,517 | 23,898 | 385,905 | Dec 18 |
| Looker Benjamin | General Counsel | Oct 17 '25 | Sale | 2.62 | 1,248 | 3,275 | 392,422 | Oct 20 |
| Looker Benjamin | General Counsel | Sep 17 '25 | Sale | 2.80 | 6,267 | 17,573 | 393,670 | Sep 18 |
| Koenig Sheldon L. | President and CEO | Sep 17 '25 | Sale | 2.79 | 28,427 | 79,254 | 1,518,831 | Sep 18 |
| Halladay Benjamin | Chief Financial Officer | Sep 17 '25 | Sale | 2.81 | 7,046 | 19,785 | 474,862 | Sep 18 |
| Looker Benjamin | General Counsel | Jul 17 '25 | Sale | 1.13 | 1,304 | 1,470 | 399,937 | Jul 18 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.